Patents Examined by D Margaret M Seaman
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 11000515
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 11, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
    Patent number: 11001558
    Abstract: The invention provides novel asymmetric and symmetric bisaminoquinolmes and related compounds, methods of treatment and syntheses. The novel compounds exhibit effective anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: May 11, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ravi K. Amaravadi, Jeffrey Winkler
  • Antiviral drug for severe fever with thrombocytopenia syndrome
    Patent number: 11001557
    Abstract: The present invention pertains to an antiviral drug for severe fever with thrombocytopenia syndrome, which contains a compound represented by formula (I) or a salt thereof, or a solvate of the compound or salt (In the formula, R1 and R2 are the same or different from each other, and each represents a substituted or unsubstituted C1-10 alkyl group, R1 and R2 may form a substituted or unsubstituted 5- or 6-member ring in conjunction with an adjacent nitrogen atom, and X represent a halogen atom.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: May 11, 2021
    Assignees: Kagoshima University, Nobelpharma Co., Ltd.
    Inventors: Masanori Baba, Masaaki Toyama, Norikazu Sakakibara
  • Aryl hydrocarbon receptor (AHR) modulator compounds
    Patent number: 10981908
    Abstract: The present invention relates to compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: April 20, 2021
    Assignee: Phenex Pharmaceuticals AG
    Inventors: Christoph Steeneck, Ulrich Deuschle, Michael Albers, Thomas Hoffmann
  • Use of quinoline derivatives for the treatment of inflammatory diseases
    Patent number: 10981874
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: April 20, 2021
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau, Romain Najman
  • Methods and compositions for modulating Akt3 activity
    Patent number: 10980878
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: April 20, 2021
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan, Iryna Lebedyeva, Thomas Albers
  • Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
    Patent number: 10973805
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: April 13, 2021
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl
  • Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
    Patent number: 10975067
    Abstract: Provided herein are novel compounds, pharmaceutical compositions for use, inter alia, in methods of reducing Wnt-mediated effects and treating cancer.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: April 13, 2021
    Assignee: STEMSYNERGY THERAPEUTICS, INC.
    Inventor: Darren Orton
  • Derivatives and their use as selective inhibitors of caspase-2
    Patent number: 10961219
    Abstract: The present invention relates to a compound of formula (I) wherein P1, P3, P4 and P5 are amino acid residues. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It also concerns the use of a compound of formula (I) as activity base probe to selectively detect Caspase-2 activity.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: March 30, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT-PARIS 7
    Inventor: Etienne Jacotot
  • Small molecule modulators of the androgen receptor
    Patent number: 10961216
    Abstract: Provided herein are compounds useful for modulating the activity of an androgen receptor, or a variant thereof, and related compositions and methods. Compounds of the invention are useful for antagonizing the androgen receptor splice variant AR-v7, and for the treatment of castration-resistant prostate cancer.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: March 30, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: David Freeman, Nicholas B. Struntz, Shelby K. Doyle, Andre Richters, Angela N. Koehler
  • Farnesoid X receptor agonists and uses thereof
    Patent number: 10961198
    Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 30, 2021
    Assignee: METACRINE, INC.
    Inventors: Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 10940139
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 9, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Bicyclic amide compounds and methods of use thereof
    Patent number: 10933036
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: March 2, 2021
    Assignee: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 10933054
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 2, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Farnesoid X receptor agonists and uses thereof
    Patent number: 10927082
    Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: February 23, 2021
    Assignee: METACRINE, INC.
    Inventors: Nicholas D. Smith, Stephen P. Govek, Johnny Y. Nagasawa
  • Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
    Patent number: 10927123
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: February 23, 2021
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Thuy-Anh Tran, Quyen-Quyen Do, Brett Ullman, Anthony C. Blackburn, Maiko Nagura
  • Tetradentate platinum (II) and palladium (II) complexes, devices, and uses thereof
    Patent number: 10930865
    Abstract: The complexes disclosed herein are cyclometalated metal complexes of Formula (I) that are useful for full color displays and lighting applications.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: February 23, 2021
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Zhi-Qiang Zhu
  • Respiratory infection treating agent
    Patent number: 10918634
    Abstract: [Problem] The present invention pertains to a safer and more effective respiratory infection treating agent. [Solution] A respiratory infection treating agent containing, as an active ingredient, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: February 16, 2021
    Assignee: KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Kota Kume, Hisao Yoshida, Hirotaka Ando, Yuta Tanaka
  • Process for the preparation of crystalline form C of avibactam sodium
    Patent number: 10919893
    Abstract: The invention relates to a process for the preparation of avibactam sodium in polymorphic form C comprising the steps (i) providing a mixture comprising avibactam or a salt thereof and a solvent, wherein the mixture has a water content of less than 2% by weight based on the weight of the mixture; (ii) increasing the temperature of the mixture provided in (i) to at least 55° C. and providing a positive pressure; adding a sodium source to the mixture in step (i) and/or (ii) if the form of avibactam provided in (i) is not avibactam sodium; thereby obtaining avibactam sodium in polymorphic form C.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: February 16, 2021
    Assignee: Sandoz AG
    Inventors: Michael Fischer, Veronika Werner, Andreas Lechner, Brigitte Staggl
  • Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Patent number: 10919859
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner, Stefan Peters